ArticleFrontiers in immunology2026
Multi-omics analyses demonstrate complement dysregulation is involved in focal segmental glomerulosclerosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The complement system is increasingly recognized as a contributor to the pathogenesis of focal segmental glomerulosclerosis (FSGS). However, a comprehensive, tissue-based characterization of complement dysregulation in human FSGS kidneys remains lacking. Methods: We performed an integrative multi-omics analysis combined with histological validation. Proteomic (LC-MS/MS) profiling was conducted on renal cortical tissues from 11 patients with FSGS and 12 healthy controls from our institution, while transcriptomic (RNA-seq) analysis was performed using publicly available datasets comprising 100 FSGS and 30 normal samples. Results: Multi-omics analyses consistently identified the complement and coagulation cascades among the most significantly enriched pathways in FSGS. Transcriptomic data revealed upregulation of C1QB, C1R, C1S, C2, C3, and CFB mRNA, whereas proteomic profiling showed upregulation of C4BPA, C5, C8B, C8G, and CFHR5, along with downregulation of C1R, C1S, C2, CFB, and CFH. In Tmem30a knocked down mouse podocytes, complement pathway enrichment was observed, but core components including C3, C1r, C1s, and CFB were downregulated. Immunofluorescence confirmed frequent glomerular C3c deposition (43.75%), with lower positivity rates for C1q (15.63%), CFB (12.5%), and CFH (12.5%); MBL deposition was rare. Patients with glomerular deposition of C3c, C1q, CFB, or CFH exhibited significantly lower probabilities of achieving complete remission. Conclusions: This study systematically demonstrates concurrent dysregulation of the classical and alternative complement pathways in FSGS. The deposition of specific complement components in renal tissue strongly correlates with disease activity, treatment resistance, and poor prognosis, suggesting their potential as pathological biomarkers and therapeutic targets. These findings enhance the understanding of FSGS immunopathogenesis and support the strategy of complement-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.